[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Singlera Genomics Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100480446","ctdna-methylation-application-in-postoperative-relapse-and-adjuvant-chemotherapy-efficacy-evaluation-100480446",false,"NCT05536089","ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation","ctDNA Methylation Used to Monitor Postoperative Relapse and Evaluate Adjuvant Chemotherapy Efficacy in Resected Stage I and Stage II (Without High Risk) Colorectal Cancer After Radical Resection","Inclusion Criteria:\n\n* Patients must have histologically confirmed stage I\u002FII (without high risk) colorectal cancer.\n* Male or female ≥ 18 years of age on the day of signing informed consent.\n* Patients need to receive surgical resection, and with ctDNA positive prior to resection of colorectal cancer (CRC).\n* Patients must have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer, colorectal adenoma or aerodigestive tract cancer.\n* Induction of neoadjuvant systemic therapy prior to resection of CRC.\n* Patient is pregnant or lactating.\n* Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.\n* Inadequate tumor material (either quality and quantity) to support circulating tumor DNA (ctDNA) analysis.","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","5 Years","OBSERVATIONAL","In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in resected stage I and stage II (without high risk) colorectal cancer after radical resection.",[25],"Cancer Colorectal",[27],"early detection","RECRUITING","2024-05-21",{"date":31,"type":32},"2024-05-22","ACTUAL",{"date":34,"type":32},"2022-09-05",{"date":36,"type":20},"2028-12",{"name":38,"class":39},"Singlera Genomics Inc.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100476526","a-prospective-cohort-study-on-colorectal-cancer-screening-in-community-population-100476526","NCT05485077","A Prospective Cohort Study on Colorectal Cancer Screening in Community Population","Colorectal Cancer Screening Cohort Study in Shougang Community Population Based on Polygene Methylation Detection Technology","Inclusion Criteria:\n\n1. Chronological age ≥40 years;\n2. Full capacity for action;\n3. After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews;\n4. In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers;\n\nExclusion Criteria:\n\n1. History of colorectal cancer and other malignant tumors;\n2. Previous colorectal resection;\n3. undergoing any cancer-related treatment;\n4. Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months;\n5. Participate in other interventional clinical investigators within 3 months;\n6. Pregnant or lactating women;\n7. Have autoimmune disease, hereditary disease, mental illness\u002Fdisability, etc\n8. Poor compliance, unable to complete the study.",true,"40 Years",{"count":51,"type":20},18000,"This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.",[54],"Colorectal Cancer",[56,57],"ctDNA methylation","Community population screening","2024-04-15",{"date":60,"type":32},"2024-04-17",{"date":62,"type":32},"2022-07-09",{"date":64,"type":20},"2028-07-09",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100465118","a-community-population-screening-cohort-study-based-on-polygene-methylation-detection-for-colorectal-cancer-in-yangzhou-100465118","NCT05336539","A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou","Inclusion Criteria:\n\n* 1\\) Permanent resident population of Yangzhou; 2) Chronological age: 40\\~74 years, including critical value (refer to birth date of id card); 3) Have full capacity of conduct; 4) After enrollment, they could voluntarily cooperate to complete the Colorectal cancer Risk Factor Assessment Questionnaire and accept telephone follow-up; 5) Agree to timely feed back the information related to tumor diagnosis to the investigator during the study process; 6) Willing and able to sign informed consent.\n\nExclusion Criteria:\n\n* 1\\) History of colorectal cancer and other malignant tumors; 2) previous colorectal resection; 3) are receiving any cancer-related treatment; 4) Those who have received major surgical treatment such as blood transfusion and transplantation within 3 months; 5) Participate in other interventional clinical investigators within 3 months; 6) Pregnant or lactating women; 7) Patients with autoimmune diseases, genetic diseases, mental diseases\u002Fdisabilities and other diseases considered unsuitable for the study by the researcher; 8) Poor compliance, unable to complete the study according to the judgment of the researcher.","74 Years",{"count":74,"type":20},80000,"This is a cross-sectional cohort study based on community population jointly developed by Northern Jiangsu People's Hospital and Shanghai Kunyuan Biological Technology Co., LTD. This study will verify the real world results of polygene methylation detection of colorectal cancer in a large prospective cohort of community population, which is expected to enroll 80,000 permanent residents in Yangzhou city. The preliminary design period of the study is 5 years. In this study, questionnaire survey and polygene methylation test of colorectal cancer were used as the primary screening method, and colonoscopy was used as the further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination. The evaluation indexes include sensitivity, specificity, detection rate of precancerous lesions and adenoma.",[54],[78,79,80],"Polygenic methylation","The community crowd","Colorectal cancer screening","2023-08-25",{"date":83,"type":32},"2023-08-29",{"date":85,"type":32},"2022-04-01",{"date":87,"type":20},"2027-04",{"name":38,"class":39},2,""]